Cyclophosphamide and Liver Disease
Author Information
Author(s): de Jonge M E, Huitema A D R, Beijnen J H, Rodenhuis S
Primary Institution: The Netherlands Cancer Institute
Hypothesis
Is there a relationship between the pharmacokinetics of cyclophosphamide and the occurrence of veno-occlusive disease of the liver (VOD)?
Conclusion
Higher exposures to 4-hydroxycyclophosphamide in the first course are predictive of the occurrence of VOD after subsequent chemotherapy courses.
Supporting Evidence
- The study included 59 patients who received high-dose chemotherapy.
- Four patients developed veno-occlusive disease after treatment.
- Significant relationships were found between drug exposure and liver damage.
Takeaway
This study found that taking too much of a certain medicine can hurt your liver, especially if you take it more than once.
Methodology
Patients received high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin, and blood samples were taken to analyze drug levels.
Limitations
The study had a low incidence of VOD, with only four patients affected.
Participant Demographics
Patients included those with high-risk primary breast cancer, metastatic breast cancer, refractory germ-cell cancer, and metastatic ovarian cancer.
Statistical Information
P-Value
0.003
Statistical Significance
p=0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website